EP2725031A4 - C-glycoside derivatives - Google Patents

C-glycoside derivatives

Info

Publication number
EP2725031A4
EP2725031A4 EP12805011.9A EP12805011A EP2725031A4 EP 2725031 A4 EP2725031 A4 EP 2725031A4 EP 12805011 A EP12805011 A EP 12805011A EP 2725031 A4 EP2725031 A4 EP 2725031A4
Authority
EP
European Patent Office
Prior art keywords
glycoside derivatives
glycoside
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12805011.9A
Other languages
German (de)
French (fr)
Other versions
EP2725031B1 (en
EP2725031A1 (en
Inventor
Frank Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Xuanzhu Pharma Co Ltd
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Publication of EP2725031A1 publication Critical patent/EP2725031A1/en
Publication of EP2725031A4 publication Critical patent/EP2725031A4/en
Application granted granted Critical
Publication of EP2725031B1 publication Critical patent/EP2725031B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/29—Saturated compounds containing keto groups bound to rings
    • C07C49/327—Saturated compounds containing keto groups bound to rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/29—Saturated compounds containing keto groups bound to rings
    • C07C49/35—Saturated compounds containing keto groups bound to rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds
EP12805011.9A 2011-06-25 2012-06-25 C-glycoside derivatives Active EP2725031B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110188186 2011-06-25
CN201110435397 2011-12-22
PCT/CN2012/000868 WO2013000275A1 (en) 2011-06-25 2012-06-25 C-glycoside derivatives

Publications (3)

Publication Number Publication Date
EP2725031A1 EP2725031A1 (en) 2014-04-30
EP2725031A4 true EP2725031A4 (en) 2014-12-03
EP2725031B1 EP2725031B1 (en) 2016-08-03

Family

ID=47423418

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12805011.9A Active EP2725031B1 (en) 2011-06-25 2012-06-25 C-glycoside derivatives

Country Status (7)

Country Link
US (2) US9562029B2 (en)
EP (1) EP2725031B1 (en)
JP (1) JP5875678B2 (en)
KR (1) KR101719758B1 (en)
CN (1) CN102875503B (en)
HK (1) HK1191653A1 (en)
WO (1) WO2013000275A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562029B2 (en) 2011-06-25 2017-02-07 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US9394329B2 (en) 2013-09-27 2016-07-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
EP2891654B1 (en) 2014-01-03 2016-06-22 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
CN104761522B (en) * 2014-01-03 2017-02-15 山东轩竹医药科技有限公司 Optically pure benzyl-4-chlorophenyl C-glucoside derivatives
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
CN105017236A (en) * 2014-04-14 2015-11-04 上海迪诺医药科技有限公司 C-aryl glucoside derivative, as well as medical composition, preparation method and application thereof
CN105001213B (en) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-aryl glycoside derivative, pharmaceutical composition, preparation method and application thereof
KR101721914B1 (en) 2015-07-13 2017-04-03 한국항공우주연구원 Container for transportation including folding cart
US11081647B2 (en) * 2016-04-22 2021-08-03 Universal Display Corporation Organic electroluminescent materials and devices
US10793588B2 (en) 2016-05-28 2020-10-06 Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. Crystal form of sodium-glucose cotransporter 2 inhibitor
WO2019185026A1 (en) * 2018-03-30 2019-10-03 南京明德新药研发有限公司 Glucoside derivatives acting as inhibitors of sglts, and use thereof
CN110551088B (en) * 2018-06-01 2022-10-21 北京惠之衡生物科技有限公司 Deuterium-modified benzyl-4-chlorophenyl C-glycoside derivatives
CN113248554A (en) * 2021-06-25 2021-08-13 北京惠之衡生物科技有限公司 Method for synthesizing impurities of C-glucoside derivatives

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000149320A (en) * 1998-11-05 2000-05-30 Mitsui Chemicals Inc Optical recording medium
WO2003035650A1 (en) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
US20040082779A1 (en) * 1999-08-04 2004-04-29 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2005092877A1 (en) * 2004-03-16 2005-10-06 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
EP1696708A1 (en) * 2003-12-15 2006-08-30 Idemitsu Kosan Co., Ltd. Material for organic electroluminescent device and organic electroluminescent device using same
TW200846441A (en) * 2007-05-17 2008-12-01 Tetrahedron Technology Corp Fluorescence main host material and organic electroluminescence device using the material
US20100171418A1 (en) * 2009-01-06 2010-07-08 Fujifilm Corporation Organic electroluminescent device
WO2010147430A2 (en) * 2009-06-19 2010-12-23 Green Cross Corporation Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
KR20110065978A (en) * 2009-12-10 2011-06-16 엘지디스플레이 주식회사 Red phosphorescene host compounds and organic light emitting devices using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558287A (en) 1995-02-02 1996-09-24 Lucent Technologies Inc. Apparatus and method to prevent flailing damage to a strand wound on a spool
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4651934B2 (en) * 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 Benzylphenol derivative, pharmaceutical composition containing it, and pharmaceutical use thereof
KR20050090437A (en) 2003-01-03 2005-09-13 브리스톨-마이어스 스큅 컴퍼니 Methods of producing c-aryl glucoside sglt2 inhibitors
JP2004300102A (en) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application
DE102004012676A1 (en) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis)
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
CN101490028B (en) 2006-05-19 2013-02-06 大正制药株式会社 C-phenyl glycitol compound
EP3318562A3 (en) 2007-08-23 2018-09-12 Theracos Sub, LLC Benzylbenzene derivatives and methods of use
HUE035072T2 (en) 2010-03-18 2018-05-02 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
US9562029B2 (en) 2011-06-25 2017-02-07 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000149320A (en) * 1998-11-05 2000-05-30 Mitsui Chemicals Inc Optical recording medium
US20040082779A1 (en) * 1999-08-04 2004-04-29 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2003035650A1 (en) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
EP1696708A1 (en) * 2003-12-15 2006-08-30 Idemitsu Kosan Co., Ltd. Material for organic electroluminescent device and organic electroluminescent device using same
WO2005092877A1 (en) * 2004-03-16 2005-10-06 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
TW200846441A (en) * 2007-05-17 2008-12-01 Tetrahedron Technology Corp Fluorescence main host material and organic electroluminescence device using the material
US20100171418A1 (en) * 2009-01-06 2010-07-08 Fujifilm Corporation Organic electroluminescent device
WO2010147430A2 (en) * 2009-06-19 2010-12-23 Green Cross Corporation Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
KR20110065978A (en) * 2009-12-10 2011-06-16 엘지디스플레이 주식회사 Red phosphorescene host compounds and organic light emitting devices using the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAWANO, YASUHIKO ET AL: "Preparation of furo[2,3-h]isoquinoline derivatives as viral entry inhibitors against HIV", XP002730919, retrieved from STN Database accession no. 2003:335106 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PH BUU-HOI, NG. ET AL: "3-Bromo-4-hydroxybiphenyl", XP002730917, retrieved from STN Database accession no. 1961:22768 *
GUO, HAI-MING ET AL: "Pd(II)-Catalyzed Ortho Arylation of 6-Arylpurines with Aryl Iodides via Purine-Directed C-H Activation: A New Strategy for Modification of 6-Arylpurine Derivatives", ORGANIC LETTERS, vol. 13, no. 8, 24 March 2011 (2011-03-24), pages 2008 - 2011, XP002730921, ISSN: 1523-7052, DOI: 10.1021/OL200405W *
PH BUU-HOI, NG. ET AL: "3-Bromo-4-hydroxybiphenyl", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, vol. 2, 1960, pages 335 - 337, ISSN: 0037-8968 *
See also references of WO2013000275A1 *
YANG, CHIHAE ET AL: "Building Predictive Models for Protein Tyrosine Phosphatase 1B Inhibitors Based on Discriminating Structural Features by Reassembling Medicinal Chemistry Building Blocks", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 24, 23 October 2004 (2004-10-23), pages 5984 - 5994, XP002730918, ISSN: 0022-2623, DOI: 10.1021/JM0497242 *

Also Published As

Publication number Publication date
EP2725031B1 (en) 2016-08-03
CN102875503B (en) 2016-05-25
EP2725031A1 (en) 2014-04-30
US20140128331A1 (en) 2014-05-08
US20170101388A1 (en) 2017-04-13
KR101719758B1 (en) 2017-03-24
WO2013000275A1 (en) 2013-01-03
KR20140057527A (en) 2014-05-13
JP5875678B2 (en) 2016-03-02
US9562029B2 (en) 2017-02-07
US10253010B2 (en) 2019-04-09
CN102875503A (en) 2013-01-16
JP2014520163A (en) 2014-08-21
HK1191653A1 (en) 2014-08-01

Similar Documents

Publication Publication Date Title
HRP20180646T1 (en) Dispiropyrrolidine derivative
HK1203196A1 (en) Substituted benzylpyrazoles
ZA201401884B (en) New dihydroquinoline-2-one derivatives
IL227664A0 (en) Novel heterocyclic derivatives
IL247639B (en) Heteroarylpiperidine derivatives
EP2739613A4 (en) Flavonoid compounds
GB201107176D0 (en) Pyrrolnitrin derivatives
HK1191653A1 (en) C-glycoside derivatives c-
IL231950B (en) Aryl-quinoline derivatives
EP2721029A4 (en) Imidazopyridin-2-one derivatives
HK1200314A1 (en) R()-n-methyl-propargyl-aminoindan r()-n---
HK1200315A1 (en) R()-n-formyl-propargyl-aminoindan r()-n---
EP2687531A4 (en) Tetrahydrocarboline derivative
ZA201402453B (en) Insecticidal 2-methoxybenzamide derivatives
EP2740730A4 (en) Dibenzooxepin derivative
IL233001A0 (en) Novel iso-ergoline derivatives
SI2766342T1 (en) Phenyl-guanidine derivatives
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201119961D0 (en) Antibacterial derivatives
GB201119958D0 (en) Antibacterial derivatives
GB201121669D0 (en) Formula 1 - 2050
GB201121656D0 (en) Formula 1 - 2050
ZA201103204B (en) Phenylpyrazole derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191653

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 307/77 20060101ALI20141015BHEP

Ipc: A61P 3/04 20060101ALI20141015BHEP

Ipc: A61K 31/7036 20060101ALI20141015BHEP

Ipc: A61P 3/10 20060101ALI20141015BHEP

Ipc: C07D 307/94 20060101ALI20141015BHEP

Ipc: A61P 3/08 20060101ALI20141015BHEP

Ipc: A61K 31/337 20060101ALI20141015BHEP

Ipc: A61K 31/7048 20060101ALI20141015BHEP

Ipc: C07H 15/203 20060101AFI20141015BHEP

Ipc: A61K 31/7034 20060101ALI20141015BHEP

Ipc: C07D 311/96 20060101ALI20141015BHEP

Ipc: A61K 31/35 20060101ALI20141015BHEP

Ipc: A61K 31/352 20060101ALI20141015BHEP

Ipc: A61K 31/7042 20060101ALI20141015BHEP

Ipc: A61K 31/335 20060101ALI20141015BHEP

Ipc: C07D 305/00 20060101ALI20141015BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7048 20060101ALI20141021BHEP

Ipc: C07D 311/96 20060101ALI20141021BHEP

Ipc: A61K 31/335 20060101ALI20141021BHEP

Ipc: A61K 31/352 20060101ALI20141021BHEP

Ipc: A61K 31/7034 20060101ALI20141021BHEP

Ipc: A61P 3/08 20060101ALI20141021BHEP

Ipc: A61P 3/10 20060101ALI20141021BHEP

Ipc: A61K 31/7042 20060101ALI20141021BHEP

Ipc: A61K 31/7036 20060101ALI20141021BHEP

Ipc: C07D 307/77 20060101ALI20141021BHEP

Ipc: A61P 3/04 20060101ALI20141021BHEP

Ipc: A61K 31/337 20060101ALI20141021BHEP

Ipc: C07D 307/94 20060101ALI20141021BHEP

Ipc: C07H 15/203 20060101AFI20141021BHEP

Ipc: C07D 305/00 20060101ALI20141021BHEP

Ipc: A61K 31/35 20060101ALI20141021BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20141103

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/04 20060101ALI20141027BHEP

Ipc: A61K 31/337 20060101ALI20141027BHEP

Ipc: A61P 3/08 20060101ALI20141027BHEP

Ipc: A61P 3/10 20060101ALI20141027BHEP

Ipc: A61K 31/35 20060101ALI20141027BHEP

Ipc: C07H 15/203 20060101AFI20141027BHEP

Ipc: C07D 305/00 20060101ALI20141027BHEP

Ipc: A61K 31/7034 20060101ALI20141027BHEP

Ipc: A61K 31/7036 20060101ALI20141027BHEP

Ipc: A61K 31/7042 20060101ALI20141027BHEP

Ipc: C07D 307/77 20060101ALI20141027BHEP

Ipc: A61K 31/335 20060101ALI20141027BHEP

Ipc: C07D 311/96 20060101ALI20141027BHEP

Ipc: C07D 307/94 20060101ALI20141027BHEP

Ipc: A61K 31/7048 20060101ALI20141027BHEP

Ipc: A61K 31/352 20060101ALI20141027BHEP

17Q First examination report despatched

Effective date: 20160119

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

INTG Intention to grant announced

Effective date: 20160524

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WU, FRANK

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 817280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012021282

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160803

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 817280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161103

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161203

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161205

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012021282

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1191653

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161103

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20170504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160803

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: HUISHENG BIOPHARMACEUTICAL CO., LTD., MEIHEKOU, CN

Free format text: FORMER OWNER: XUANZHU PHARMA CO., LTD., JINAN, SHANDONG, CN

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012021282

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., CN

Free format text: FORMER OWNER: XUANZHU PHARMA CO., LTD., JINAN, SHANDONG, CN

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, , CN

Free format text: FORMER OWNER: XUANZHU PHARMA CO., LTD., JINAN, SHANDONG, CN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: HUISHENG BIOPHARMACEUTICAL CO., LTD., MEIHEKOU, CN

Free format text: FORMER OWNERS: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., BEIJING, CN; JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, MELHEKOU, JILIN, CN

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., CN

Free format text: FORMER OWNERS: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., BEIJING, CN; JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, MELHEKOU, JILIN, CN

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, , CN

Free format text: FORMER OWNERS: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., BEIJING, CN; JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, MELHEKOU, JILIN, CN

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012021282

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20210617 AND 20210623

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230510

Year of fee payment: 12

Ref country code: DE

Payment date: 20230502

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: HUISHENG BIOPHARMACEUTICAL CO., LTD., MEIHEKOU, CN

Free format text: FORMER OWNERS: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., BEIJING, CN; JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, MEIHEKOU, JILIN, CN

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012021282

Country of ref document: DE

Owner name: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., CN

Free format text: FORMER OWNERS: BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD., BEIJING, CN; JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD, MEIHEKOU, JILIN, CN

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230504

Year of fee payment: 12